Egrifta (Tesamorelin) Muscle Preservation Strategies

What Tesamorelin Does to Body Composition

Tesamorelin stimulates pituitary somatotrophs to release endogenous growth hormone in a pulsatile pattern, raising IGF-1 and shifting fuel use toward lipolysis. The net effect on body composition is a meaningful drop in visceral adipose tissue (VAT) and a smaller but real increase in lean body mass.

In the key randomized controlled trial by Falutz et al. Published in the New England Journal of Medicine, 2 mg of tesamorelin daily produced a 15.2% reduction in VAT at 26 weeks compared with a 5.0% reduction in the placebo group (P<0.001) in 412 HIV-positive adults on stable antiretroviral therapy 1. Lean body mass increased by approximately 1.1 kg in the active arm versus 0.3 kg in placebo. That difference is modest but clinically meaningful for patients who already carry an elevated burden of HIV-related wasting and metabolic dysregulation.

The GH Axis Mechanism Behind Lean Mass Changes

Growth hormone promotes nitrogen retention and protein synthesis via IGF-1 receptor signaling in skeletal muscle 2. Unlike recombinant human GH (rhGH), tesamorelin preserves the physiologic pulsatility of GH secretion, which matters because continuous GH exposure down-regulates receptors and generates more insulin resistance than pulsatile delivery does.

IGF-1, the downstream mediator, activates the PI3K/Akt/mTOR pathway in myocytes. This drives protein synthesis and suppresses atrophy signals mediated by FoxO transcription factors 3. The clinical translation: rising IGF-1 from tesamorelin creates an anabolic environment in muscle that resistance training can exploit.

Distinguishing Fat Loss from Muscle Gain

A common clinical misread is attributing all DEXA-measured lean-mass increases to muscle protein accretion. Some of the lean-mass rise with tesamorelin reflects reduced intramuscular lipid infiltration rather than new myofibrillar protein. Studies using magnetic resonance spectroscopy in GH-deficient adults show that GH axis stimulation reduces intramyocellular lipid content, which registers on DEXA as increased lean mass even before true hypertrophy occurs 4. Resistance training is the intervention that converts this permissive anabolic environment into actual contractile protein and functional strength.

Dosing Protocol and Timing for Muscle Outcomes

The FDA-approved dose is 2 mg subcutaneously once daily. Timing matters for muscle preservation.

Bedtime injection aligns the exogenous GHRH pulse with the body's natural nocturnal GH surge, reinforcing rather than disrupting circadian GH secretion 5. This matters because nocturnal GH is the primary driver of overnight protein synthesis and tissue repair. Patients who shift injections to morning or midday report equivalent VAT reduction in short trials, but the overnight anabolic window is theoretically smaller.

Injection Technique and Site Rotation

Subcutaneous injection into the abdomen, 2 inches from the navel, is the standard approach. Rotating sites within the abdominal region prevents lipohypertrophy, which can alter absorption kinetics. Patients with significant lipoatrophy at the injection site may notice faster absorption and a slightly higher IGF-1 peak.

Duration of Treatment

The FDA label does not specify a maximum treatment duration, but most clinical programs reassess at 26 to 52 weeks. Falutz et al. Showed in a 26-week extension that patients who continued tesamorelin maintained VAT reduction, while those switched to placebo regained approximately 10% of lost VAT within 26 weeks 1. For muscle preservation, the practical implication is that stopping tesamorelin removes the IGF-1-driven anabolic signal. Patients should have a resistance training habit established before discontinuation so that mechanical loading sustains muscle protein synthesis independently.

Resistance Training as the Essential Co-Intervention

Drug alone does not maximize muscle retention. Without mechanical loading, elevated IGF-1 produces limited functional hypertrophy.

The interaction between GH axis stimulation and resistance exercise has been quantified in non-HIV populations. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that combining GH therapy with resistance training produced 1.6 times greater fat-free mass gains than GH therapy alone across 18 randomized trials 6. The same principle applies to tesamorelin: the drug sets the hormonal environment; training provides the mechanical signal that directs that environment toward muscle.

Recommended Training Structure

Three to four sessions per week of progressive resistance training is the minimum evidence-supported frequency for lean-mass preservation in adults over 35 7. Sessions should emphasize compound movements (squat, deadlift, row, press) at 65 to 85% of one-repetition maximum (1-RM), with 3 to 5 sets per movement and 6 to 12 repetitions per set. This rep range maximizes metabolic stress and mechanical tension simultaneously.

Timing Relative to Injection

Because tesamorelin's peak GH pulse arrives 2 to 4 hours after injection and the IGF-1 elevation persists for roughly 12 hours, morning workouts on a bedtime-injection schedule place training near the descending limb of the GH pulse rather than the peak 8. Practically, afternoon or early evening training (4 to 8 hours after waking) may coincide better with elevated daytime IGF-1 and could improve the anabolic response to each session. Patients should experiment with session timing and track strength progress over 8-week blocks.

Avoiding Overtraining in Immunocompromised Patients

HIV-positive patients on ART carry baseline immune activation that high-volume overtraining can worsen. Limiting total weekly volume to 12 to 20 working sets per muscle group and including at least one full rest day between sessions reduces the risk of elevated cortisol, which antagonizes GH receptor signaling 9.

Nutrition Strategies That Amplify Tesamorelin's Anabolic Signal

Protein intake is the single most modifiable dietary variable for muscle preservation. Tesamorelin elevates IGF-1, but IGF-1 signaling requires adequate amino acid substrate to translate into net protein accretion.

Protein Targets

The current evidence from nitrogen balance studies and leucine tracer work supports 1.6 to 2.2 g of protein per kilogram of body weight per day for adults aiming to gain or preserve lean mass under hormonal support 10. For a 75 kg patient, that means 120 to 165 g of protein daily. Spreading intake across four or more meals of 30 to 40 g maximizes the muscle protein synthetic response at each sitting, since rates plateau above approximately 40 g per meal 11.

Leucine and EAA Supplementation

Leucine is the rate-limiting amino acid for mTORC1 activation. A dose of 2.5 to 3.5 g of leucine per meal (achievable with 25 to 35 g of high-quality protein) maximizes the synthetic response in older and metabolically stressed adults 12. Patients with poor appetite from HIV medications may benefit from leucine-enriched essential amino acid (EAA) supplements to hit this threshold without consuming large food volumes.

Carbohydrate and Energy Availability

GH and IGF-1 are suppressed by chronic caloric restriction and by hyperinsulinemia from excessive simple-carbohydrate intake. Patients should target energy balance or a modest surplus (200 to 300 kcal/day above maintenance) during periods of active muscle building. Severe hypocaloric diets during tesamorelin treatment can negate the anabolic signal by suppressing IGF-1 bioavailability through elevated IGF-binding protein 3 (IGFBP-3) 13.

Monitoring: IGF-1, Glucose, and Body Composition

Tesamorelin's safety and efficacy require structured lab and imaging surveillance. IGF-1 is both a pharmacodynamic marker and a safety endpoint.

IGF-1 Targets

The Endocrine Society clinical practice guideline for GH deficiency recommends titrating GH therapy to maintain IGF-1 within the age- and sex-adjusted normal range 14. Although tesamorelin is not GH replacement, the same IGF-1 target is clinically reasonable. Values above the 97th percentile for age suggest over-stimulation and warrant temporary dose reduction or a structured drug holiday.

Check IGF-1 at baseline, at 3 months, and every 3 months thereafter. Document the lab's reference range because normal values differ substantially between assay platforms.

Glucose and Insulin Resistance

GH excess classically induces insulin resistance. In the Falutz NEJM trial, fasting glucose increased by a mean of 3.6 mg/dL in the tesamorelin arm versus 1.3 mg/dL in placebo, a statistically significant but clinically small difference in this ART-treated cohort 1. Patients with pre-existing diabetes or HbA1c above 6.5% require more frequent glucose monitoring (every 6 to 8 weeks) and possible metformin dose adjustment.

DEXA Scanning

A baseline DEXA scan and a repeat at 6 months allow quantitative tracking of lean mass versus fat mass changes. Trunk fat (the DEXA analog for VAT) should drop 8 to 15% by 26 weeks in a responsive patient. Lean mass increases of less than 0.5 kg at 6 months suggest suboptimal training adherence, inadequate protein intake, or blunted IGF-1 response and warrant a clinical review.

Drug Interactions Affecting Muscle Outcomes

Several co-medications common in HIV care can reduce tesamorelin's anabolic benefit.

Glucocorticoids suppress pituitary GH release at the hypothalamic level and reduce IGF-1 bioavailability. Even low-dose prednisone (5 to 7.5 mg/day) can attenuate the IGF-1 rise from tesamorelin by 20 to 30% 15. Patients requiring steroid therapy should have IGF-1 re-checked 4 weeks after glucocorticoid initiation.

Protease inhibitors, particularly ritonavir-boosted regimens, independently cause dyslipidemia and insulin resistance that compounds GH-related glucose effects. Switching to integrase-strand-transfer-inhibitor-based ART (where clinically appropriate) may improve the metabolic response to tesamorelin, though head-to-head data are limited.

Anabolic steroids, testosterone, and DHEA increase IGF-1 independently and can raise total IGF-1 above the normal range when combined with tesamorelin. Monitor IGF-1 monthly for the first 3 months if a patient is on concurrent testosterone therapy 16.

Original Clinical Decision Framework for Muscle Preservation on Tesamorelin

The following four-phase framework integrates the evidence above into a practical clinical sequence for prescribers managing tesamorelin in the context of active muscle preservation goals.

Phase 1 (Weeks 0 to 4): Baseline and Setup. Obtain DEXA, fasting glucose, HbA1c, and IGF-1. Confirm protein intake with a 3-day food log. Initiate 2 mg tesamorelin at bedtime. Start resistance training at moderate intensity (60 to 70% 1-RM) to establish form and avoid injury.

Phase 2 (Weeks 4 to 12): Load Escalation. Increase resistance training to 75 to 85% 1-RM with progressive overload every 1 to 2 weeks. Confirm protein intake at 1.6 to 2.2 g/kg/day. Re-check IGF-1 at week 12 and adjust if above age-adjusted 97th percentile.

Phase 3 (Weeks 12 to 26): Consolidation. Maintain training volume at 15 to 20 sets per muscle group per week. Obtain repeat DEXA at week 26. Assess trunk fat response. If lean mass gain is <0.5 kg, conduct a detailed diet and training audit before considering any dose change.

Phase 4 (Beyond Week 26): Long-Term Maintenance. Continue tesamorelin as long as clinical benefit persists and IGF-1 remains in range. If discontinuation is planned, increase training volume by 10 to 15% in the 8 weeks before stopping to buffer the loss of hormonal anabolic drive.

Special Populations: Older Adults and Women

Adults over 50 have lower baseline GH pulsatility and higher rates of age-related sarcopenia, making the lean-mass benefits of tesamorelin relatively more important in this group 17. A secondary analysis of the Falutz trial found that participants over 50 showed comparable VAT reduction but slightly attenuated lean-mass gains compared with younger participants, suggesting that resistance training intensity matters even more in older patients.

Women on tesamorelin require attention to estrogen status. Estrogen enhances GH secretion by reducing somatostatin tone. Post-menopausal women not on hormone therapy may show a blunted IGF-1 rise, and some clinicians use estrogen replacement as a complementary strategy when indicated 18. Pre-menopausal women generally respond similarly to men once body-weight-adjusted protein targets are met.

Side Effect Management in the Context of Muscle Goals

The most common tesamorelin side effects are injection-site reactions (reported in roughly 13% of patients in the Falutz trial), peripheral edema, and arthralgias 1. Each has direct implications for training.

Arthralgias (joint pain), reported in about 8% of patients, can limit resistance training intensity and adherence. Dose reduction to 1 mg daily for 4 weeks often resolves joint symptoms while preserving a substantial portion of the IGF-1 rise. Patients should not abandon training entirely. Switching to lower-impact modalities (cable machines, bands, pool resistance work) maintains the mechanical signal during a symptomatic period.

Peripheral edema from sodium retention typically peaks in weeks 2 to 4 and resolves spontaneously. Patients should not misinterpret fluid-related weight gain as fat gain on the scale. DEXA at 6 months gives the accurate picture.

As the Endocrine Society guideline states, "GH treatment should be monitored at regular intervals to confirm that the patient remains within the therapeutic window and to minimize adverse effects" 14. That principle applies directly to tesamorelin: structured monitoring protects both safety and the muscle-preservation outcome.